KORU Medical Systems (KRMD) Stock Overview
Develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for KRMD from our risk checks.
KRMD Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
KORU Medical Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.14 |
| 52 Week High | US$6.61 |
| 52 Week Low | US$3.12 |
| Beta | 0.42 |
| 1 Month Change | -7.65% |
| 3 Month Change | -20.30% |
| 1 Year Change | -20.30% |
| 3 Year Change | 18.05% |
| 5 Year Change | 5.37% |
| Change since IPO | 7,750.00% |
Recent News & Updates
KORU Medical Systems Selloff Offers An Opportunity
Summary KORU Medical Systems is transforming into a digitally enabled drug delivery platform, leveraging secular tailwinds in at-home subcutaneous infusion therapies. Q2 revenue grew 18.2% to $12.05M with positive net income and gross margin expansion to 65.1%, driven by domestic core strength and international growth. International ramp is slower than forecast, prompting narrowed FY guidance to $47.5M–$48.5M revenue and a raised gross margin outlook to 62%–64%. Management targets $100M revenue, gross margins above 65%, and EBITDA margins of at least 20% long-term, with positive adjusted EBITDA expected in FY26. Read the full article on Seeking AlphaKORU Medical Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
There's been a notable change in appetite for KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares in the week since its...Recent updates
KORU Medical Systems Selloff Offers An Opportunity
Summary KORU Medical Systems is transforming into a digitally enabled drug delivery platform, leveraging secular tailwinds in at-home subcutaneous infusion therapies. Q2 revenue grew 18.2% to $12.05M with positive net income and gross margin expansion to 65.1%, driven by domestic core strength and international growth. International ramp is slower than forecast, prompting narrowed FY guidance to $47.5M–$48.5M revenue and a raised gross margin outlook to 62%–64%. Management targets $100M revenue, gross margins above 65%, and EBITDA margins of at least 20% long-term, with positive adjusted EBITDA expected in FY26. Read the full article on Seeking AlphaKORU Medical Systems, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
There's been a notable change in appetite for KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares in the week since its...
KRMD: Increasing Home Infusion Adoption Will Support Higher Future Earnings Power
Analysts have raised their fair value estimate for KORU Medical Systems to $5.00 from $4.00, reflecting updated assumptions regarding revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What's in the News KORU Medical Systems presented new research at the Oncology Nursing Society Congress, highlighting its FreedomEDGE infusion system in subcutaneous monoclonal antibody administration across four U.S. community infusion centers, source: company key developments.Is There An Opportunity With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) 49% Undervaluation?
Key Insights The projected fair value for KORU Medical Systems is US$9.53 based on 2 Stage Free Cash Flow to Equity...KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Shares Climb 34% But Its Business Is Yet to Catch Up
Despite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...Investors Appear Satisfied With KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Prospects As Shares Rocket 34%
Despite an already strong run, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have been powering on, with a gain of...Market Participants Recognise KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues Pushing Shares 27% Higher
KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shareholders would be excited to see that the share price has had a great...KORU Medical Systems, Inc. (NASDAQ:KRMD) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Those holding KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares would be relieved that the share price has rebounded...KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
KORU Medical Systems, Inc. ( NASDAQ:KRMD ) shares have had a horrible month, losing 27% after a relatively good period...KORU Medical Systems, Inc. (NASDAQ:KRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.10
As you might know, KORU Medical Systems, Inc. ( NASDAQ:KRMD ) just kicked off its latest quarterly results with some...Impressive Turnaround At KORU Medical
Summary KORU Medical Systems is poised for growth with solid revenue increases, multiple growth drivers, and a chance to reach cash flow breakeven in Q4. The FREEDOM system, designed for at-home drug delivery, offers recurring revenue from consumables and is gaining market share in the SCIg market. International expansion and novel therapies present significant growth opportunities, with international revenue growing 46% and novel therapies progressing to Phase 3 trials. Financials are improving with a 22% revenue increase, 65% gross margin, and expected cash flow breakeven in Q4, making the shares a solid buy here. Read the full article on Seeking AlphaWe're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares
With a median price-to-sales (or "P/S") ratio of close to 3.2x in the Medical Equipment industry in the United States...Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues
There wouldn't be many who think KORU Medical Systems, Inc.'s ( NASDAQ:KRMD ) price-to-sales (or "P/S") ratio of 3.6x...We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Shareholder Returns
| KRMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -3.4% | -5.5% | -0.9% |
| 1Y | -20.3% | -18.1% | 13.9% |
Return vs Industry: KRMD underperformed the US Medical Equipment industry which returned -18.1% over the past year.
Return vs Market: KRMD underperformed the US Market which returned 13.9% over the past year.
Price Volatility
| KRMD volatility | |
|---|---|
| KRMD Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: KRMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: KRMD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 73 | Adam Kalbermatten | www.korumedical.com |
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 Syringe Driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing.
KORU Medical Systems, Inc. Fundamentals Summary
| KRMD fundamental statistics | |
|---|---|
| Market cap | US$145.90m |
| Earnings (TTM) | -US$1.82m |
| Revenue (TTM) | US$45.11m |
Is KRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRMD income statement (TTM) | |
|---|---|
| Revenue | US$45.11m |
| Cost of Revenue | US$16.95m |
| Gross Profit | US$28.16m |
| Other Expenses | US$29.98m |
| Earnings | -US$1.82m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 62.43% |
| Net Profit Margin | -4.03% |
| Debt/Equity Ratio | 0% |
How did KRMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 22:13 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
KORU Medical Systems, Inc. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Caitlin Cronin | Canaccord Genuity |
| null null | CG Capital |